Cambridge Healthtech Institute’s 2nd Annual

CNS and Neurodegenerative Targets
( 中枢神经系统疾病和神经变性疾病的标靶 )


The identification of therapeutic targets based on novel mechanistic approaches is urgently needed for CNS and neurodegenerative diseases, particularly for conditions such as Alzheimer’s which represent extensive unmet medical need and blockbuster potential for the right therapy.

Driven by an improving understanding of CNS disease biology and the emergence of new mechanisms and targets, Cambridge Healthtech Institute’s CNS and Neurodegenerative Targets conference profiles the latest tools, targets and platforms driving today’s CNS drug discovery strategies, with critical updates and findings in key areas such as new targets for misfolded proteins, tau, GCPRs, kinase inhibitors, genetics, gene therapy, and neuroinflammation.

Who should attend: CSOs, Vice Presidents, Directors, Managers, Researchers, and Scientists from pharma, biotechs, academia, government and healthcare organizations working in fields such as CNS drug discovery, R&D, translational & biomedical informatics, and computational biology


Coverage will include, but is not limited to:                                        

  • Latest undestanding and biology behind CNS disease - causes, proven and unproven theories
  • New ways of targeting misfolded proteins
  • Tools to discover CNS new targets
  • Impact of genetics and big data in CNS drug discovery
  • New targets: Tau, GCPRs, BACE, Kinase Inhibitors, PERK inhibitors, peptides
  • Antibody-based therapies – CD20, CD52, CTLA4, PD-L1
  • Inflammatory targets in CNS disease – role of the immune system
  • Neuroinflammation
  • Targets for CNS rare disease
  • New roles for old targets
  • Autophagy
  • Vascular Targets
  • Neuroprotective targets


* 活动内容有可能不事先告知作更动及调整。

Choose your language